“Dosing the first patient in our global Phase 3 program is a major advancement as we work to deliver a differentiated, next-generation therapy for HCV,” said Jean-Pierre Sommadossi ...

The second phase of Mumbai Metro Line 3, also known as the Aqua Line, is nearing its launch. The Commissioner of Metro Rail Safety (CMRS) began inspecting the 9.77-km underground stretch from Bandra ...

Mumbai: The much-anticipated Phase 2 of Mumbai Metro Line 3 is nearing the finish line, with the 9.8-kilometre underground stretch from Bandra Kurla Complex (BKC) to Worli (Acharya Atre Chowk ...

(RTTNews) - Late-stage clinical biopharmaceutical company Sellas Life Sciences Group, Inc. (SLS) Tuesday announced positive survival in Cohort 3 data from the ongoing Phase 2 trial of SLS009 ...

Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosis Tolebrutinib has the potential to be the ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to ...

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple ...

Credit: Getty Images In a phase 3 clinical trial, researchers assessed the efficacy and safety of inebilizumab in patients with generalized myasthenia gravis. At Week 26, compared to the placebo ...

“The remarkable results from Cohort 3 of the ongoing Phase 2 trial reinforce the potential of SLS009 to transform outcomes for these heavily pretreated AML patients,” said Angelos Stergiou, MD, ScD ...

The contracts, announced April 4 by the U.S. Space Force’s Space Systems Command, are part of the National Security Space Launch (NSSL) Phase 3 Lane 2 procurement, a cornerstone initiative ...

Roche on Thurs­day shared ear­ly pos­i­tive re­sults for its Alzheimer’s can­di­date tron­tinemab, the lat­est round of da­ta in its sec­ond at­tempt to de­vel­op a drug … ...